In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 60 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
60
Advancing Vision Research
Smyrna, Tennessee, United States
RECRUITINGOcular Itching
Ocular itching score will be reported by the subject at 3 timepoints after CAC at Visits 4d , 5d, and 6c.
Time frame: 3, 5 and 7 minutes after CAC
Conjunctival Redness
Conjunctival redness score will be evaluated by the investigator at 3 timepoints after CAC at Visits 4d, 5d, and 6c.
Time frame: 7, 15 and 20 minutes after CAC
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.